-+ 0.00%
-+ 0.00%
-+ 0.00%

What Bayer Holders Got Right Before A 94% Run

Simply Wall St·11/21/2026 06:11:12
Listen to the news

If you held Bayer through the last year, the result has been hard to ignore. For Bayer shareholders, the return over the past year was 94.0%, including dividends. That outcome followed years of arguments about whether mounting Roundup liabilities and heavy debt would choke cash generation, or whether a pharma pipeline and cost cuts would eventually prevail. If you were deciding back on 20 November 2025, which side of that debate would you have trusted?

On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.

Bayer has already moved. Pinpoint other ways to investigate the theme among 120 healthcare AI stocks.

The Argument Bayer Investors Were Really Having

The shares cost €26.98 at the start of the period, and anyone looking at Bayer then had to choose between two sharply different stories.

The bullish Narrative saw Fair Value at €28.37, about 5% above the start price, built on the assumption that a strong pharma pipeline and new launches such as Nubeqa and Kerendia would offset expiring patents and support higher margins over time.

The bearish view put Fair Value at €23, about 15% below the start price, focused on the risk that sizeable glyphosate and PCB litigation and debt of over €33b would keep cash flow and flexibility under pressure for years.

XTRA:BAYN 1-Year Stock Price Chart
XTRA:BAYN 1-Year Stock Price Chart

What The Facts Did To The Bayer Debate

The decisive event was the US Supreme Court ruling that shielded Bayer from most Roundup warning lawsuits and cleared about 65,000 cases. This clearly backed the view that litigation might be contained. Reported results added nuance. Revenue reached €10,053m in Q3 2026 compared with €9,660m a year earlier, while the business still reported a loss and a negative net margin of 6.7%, so profitability remained unproven. Overall, the evidence cut both ways.

The whole argument turned on whether Roundup liabilities would swamp cash generation or be capped while Bayer’s pipeline matured. When reviewing another stock with big legal exposure, track the size and direction of case counts, settlement frameworks and any top court decisions. Then test those against the trend in net margin rather than the share price.

What Bayer’s 94% Run Already Prices In

Today's Bayer share price is €53.36, almost double the €26.98 level from a year ago. According to Valrodmon, an investor in the Simply Wall St Community, this Narrative’s Fair Value now sits below the current price despite a constructive view on the business transition.

Valrodmon argues that the key swing factor is whether cost savings, pharma launches and Crop Science execution outweigh patent losses and Roundup litigation costs. A buyer at today’s price effectively assumes that Bayer delivers that turnaround while keeping legal cash drains contained.

"Essa narrativa otimista, no entanto, é temperada por riscos, como a perda de patentes em produtos chave e o peso contínuo de litígios relacionados ao Roundup, que continuam a drenar recursos financeiros. O mercado vê a Bayer com um misto de cautela e otimismo moderado."

That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for

Find Your Own Contrarian Opportunity

By the time a rally makes headlines, you are reading about returns someone else has already earned. Why not go straight to the source and look for your own contrarian opportunity? These three companies trade below our estimated value.

  • Company 1 - 38% below our estimate - uses AI and automation to expand programmatic trade into higher margin retail sales.
  • Company 2 - 36% below our estimate - rebuilds service profitability while working through a contracted equipment and maintenance backlog.
  • Company 3 - 46% below our estimate - shifts toward higher margin drinks in faster growing regions to offset regulatory pressures.

That is three of the list. See all 236 potentially undervalued companies →